KALA BIO (KALA) vs PRF Technologies (PRFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
KALA BIO is the larger company by market cap ($1.7 million vs $1.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KALA | PRFX |
|---|---|---|
| Share price | $2.71 | $0.4758 |
| Market cap | $1.74M | $1.66M |
| 1-day change | -10.28% | -23.68% |
| EPS (TTM) | $-321.30 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $17.00K |
| Net income (latest FY) | $-26.98M | $-5.02M |
| Gross margin | — | -311.76% |
| Operating margin | — | -30129.41% |
| Net margin | — | -29541.18% |
| 52-week high | $2,865.00 | $7.95 |
| 52-week low | $2.65 | $0.46 |
| Distance from 52-week high | -99.91% | -94.02% |
| Average volume | 52.52K | 228.55K |
| Shares outstanding | 644.66K | 3.50M |
| Employees | 6 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
KALA vs PRFX FAQ
Which is bigger, KALA BIO or PRF Technologies?
KALA BIO (KALA) is larger, with a market capitalization of $1.74M compared with $1.66M for PRF Technologies (PRFX).
Are KALA BIO and PRF Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.